SONER CANDER, ÖZEN ÖZ GÜL, Canan ERSOY, Erdinç ERTÜRK

Curative Result with Primary Medical Therapy in an Elderly Acromegaly Patient

In acromegaly, transsphenoidal hypophysectomy is the primary treatment of choice. Medical treatment is performed on patients uncontrollable with surgery. Indications for primary medical treatment or medical treatment prior to surgery are limited to patients with macroadenoma with high risk for surgery due to cardiac and respiratory problems. Medical treatment is not applied on patients with microadenoma due to the high chance of cure with surgical option. Seventy-five years-old female patient was admitted in our clinic with complaints of drowsiness, fatigue and growth in hands and feet. Patient's IGF1level was measured 516 ng/ml (64-188 ng/ml normal range for age and gender) and in the magnetic resonance imaging of the pituitary; an adenoma, 2x2 mm in size, was detected. Octreotide LAR therapy was begun 10 mg per month considering the age of the patient. IGF1 level was measured as 129ng/ml and growth hormone (GH) as 0.65ng/ml (0.06-5 ng/ml normal range) at the end of the third month of treatment. On the MRI carried out in the 9th month of treatment, it was observed that the pituitary was compatible with partial empty sella and no adenoma was determined. In our case of acromegaly with microadenoma, taking into account the age and medical condition of the patient, primary medical therapy was required. Although a low dose of octreotide LAR was implemented, primary medical therapy has been effective in controlling biochemical parameters. Moreover, it was observed that the tumor completely disappeared and is considered a curative result. Therefore, primary medical treatment of acromegaly should be among the options in selected patients with microadenomas.

PDF

___

1. Engin H, Bilir C, Üstün H, Gökmen A. ABO blood group and risk of pancreatic cancer in a Turkish population in Western Blacksea region. Asian Pac J Cancer Prev. 2012;13(1):131-3.
2. Oguz A, Unal D, Tasdemir A, Karahan S, Aykas F, Mutlu H, Cihan YB, Kanbay M. Lack of any association between blood groups and lung cancer, independent of histology. Asian Pac J Cancer Prev. 2013;14(1):453-6.
3. Utkan G, Ürün Y, Cangir AK, Kılıç D, Özdemir NY, Oztuna DG, Bulut E, Arslan ÜY, Koçer M, Kavukçu Ş, İçli F. Clinicopathological features of patients with malignant mesothelioma in a multicenter, case-control study: no role for ABO-Rh blood groups. Asian Pac J Cancer Prev. 2013;14(1):249-53.
4. Yuzhalin AE, Kutikhin AG.ABO and Rh blood groups in relation to ovarian, endometrial and cervical cancer risk among the population of South-East Siberia. Asian Pac J Cancer Prev. 2012;13(10):5091-6.
5. Wang Z, Liu L, Ji J, Zhang J, Yan M, Zhang J, Liu B, Zhu Z, Yu Y.ABO Blood Group System and Gastric Cancer: A Case-Control Study and Meta-Analysis. Int J Mol Sci. 2012;13(10):13308-21.
6. Poole EM, Gates MA, High BA, Chanock SJ, Cramer DW, Cunningham JM, Fridley BL, Gayther SA, Goode EL, Iversen ES, Lissowska J, Palmieri Weber RT, Pharoah PD, Phelan CM, Ramus SJ, Schildkraut JM, Sutphen R, Tsai YY, Tyrer J, Vierkant RA, Wentzensen N, Yang HP, Terry KL, Tworoger SS. ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium. Cancer Causes Control. 2012;23(11):1805-10.
7. Urun Y, Ozdemir NY, Utkan G, Akbulut H, Savas B, Oksuzoglu B, Oztuna DG, Dogan I, Yalcin B, Senler FC, Onur H, Demirkazik A, Zengin N, Icli F. ABO and Rh Blood Groups and Risk of Colorectal Adenocarcinoma. Asian Pac J Cancer Prev. 2012;13(12):6097-100.
8. Braganza MZ, Kitahara CM, Berrington de González A, Inskip PD, Johnson KJ, Rajaraman P. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol. 2012;14(11):1316-24.
9. Giles GG, McNeil JJ, Donnan G, Webley C, Staples MP, Ireland PD, Hurley SF, Salzberg M Dietary factors and the risk of glioma in adults: results of a case-control study in Melbourne, Australia.. Int J Cancer. 1994;59(3):357-62.
10. Inskip PD, Mellemkjaer L, Gridley G, Olsen JH.Incidence of intracranial tumors following hospitalization for head injuries (Denmark). Cancer Causes Control. 1998;9(1):109-16.
11. Chen H, Ward MH, Tucker KL, Graubard BI, McComb RD, Potischman NA, Weisenburger DD, Heineman EF. Diet and risk of adult glioma in eastern Nebraska, United States. Cancer Causes Control. 2002;13(7):647-55.
12. Schwartzbaum J, Ding B, Johannesen TB, Osnes LT, Karavodin L, Ahlbom A, Feychting M, Grimsrud TK.Association between prediagnostic IgE levels and risk of glioma. J Natl Cancer Inst. 2012;104(16):1251-9.
13. Musicco M, Sant M, Molinari S, Filippini G, Gatta G, Berrino F. A case-control study of brain gliomas and occupational exposure to chemical carcinogens: the risk to farmers. Am J Epidemiol. 1988;128(4):778-85.
14. Preston-Martin S. Descriptive epidemiology of primary tumors of the brain, cranial nerves and cranial meninges in Los Angeles County. Neuroepidemiology. 1989;8(6):283-95.
15. Savitz DA, Loomis DP.Magnetic field exposure in relation to leukemia and brain cancer mortality among electric utility workers. Am J Epidemiol. 1995;141(2):123-34.
16. Mehrazin M. ABO blood group frequency and brain tumors. Asian Pac J Cancer Prev. 2006;7(4):582-4.
17. Turowski K, Czochra M. [ABO blood groups in glioblastoma multiforme]. Neurol Neurochir Pol. 1979;13(2):173
18. Gates MA, Xu M, Chen WY, Kraft P, Hankinson SE, Wolpin BM.ABO blood group and breast cancer incidence and survival. Int J Cancer. 2012;130(9):2129-37.
19. Qiu MZ, Zhang DS, Ruan DY, Luo HY, Wang ZQ, Zhou ZW, Wang FH, Li YH, Xu RH.A relationship between ABO blood groups and clinicopathologic characteristics of patients with gastric adenocarcinoma in China. Med Oncol. 2011;28 Suppl 1:S268-73.
20. Kos FT, Civelek B, Seker MM, Arik Z, Aksoy S, Uncu D, Ozdemir N, Zengin N.Is There an Association between Blood Group and Survival in Pancreatic Cancer? Asian Pac J Cancer Prev. 2012;13(12):6151-3.
21. Kaffenberger SD, Morgan TM, Stratton KL, Boachie AM, Barocas DA, Chang SS, Cookson MS, Herrell SD, Smith JA, Clark PE.ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma. BJU Int. 2012;110(11 Pt B):E641-6